Brief: Bioarctic Receives European Substance Patent For Exidavnemab
23/04/2025 12:47
April 23 (Reuters) - BioArctic AB BIOAb.ST: BIOARCTIC RECEIVES EUROPEAN SUBSTANCE PATENT FOR EXIDAVNEMAB PATENT ENTERS INTO FORCE ON 14 MAY 2025 AND EXPIRES IN 2041, WITH POSSIBILITY OF EXTENSION UNTIL 2046. Source text: ID:nWkr97T66G Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln